Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vanrenterghem, Y.
Right arrow Articles by Vanwalleghem, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanrenterghem, Y.
Right arrow Articles by Vanwalleghem, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 13, Issue 90002 13-15, Copyright © 1998 by Oxford University Press

ORIGINAL ARTICLES

Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin

Y Vanrenterghem and J Vanwalleghem
Department of Nephrology, University Hospital Gasthuisberg, Herestraat 49, B3000 Leuven, Belgium; Corresponding author

The possibility of lower efficacy and the fear of an increased incidence of side effects may explain the reluctance to use recombinant human erythropoietin (r-HuEPO) in patients with impaired renal function who do not yet require dialysis, as well as in transplanted patients with a failing renal allograft. Several recent studies have clearly shown that r-HuEPO is effective in these patient populations and that the doses needed to control anaemia are comparable with or lower than those needed for dialysis patients. When started at a low dose, the risk of severe hypertension is minimal, although in a significant number of patients intensification of the antihypertensive regimen is needed. Moreover there are no indications that the use of r-HuEPO accelerates the deterioration of residual renal function.Key words: anaemia; erythropoietin; pre-dialysis; renal transplantation
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
O.I. Dyadyk, A.E. Bagriy, and N.F. Yarovaya
Disorders of left ventricular structure and function in chronic uremia: how often, why and what to do with it?
Eur J Heart Fail, December 17, 1999; 1(4): 327 - 336.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.